Objectives: This systematic review aimed to examine the efficacy and safety profile of amivantamab in patients with advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.